These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 23894342)

  • 1. Plasma midregional pro-adrenomedullin improves prediction of functional outcome in ischemic stroke.
    Seifert-Held T; Pekar T; Gattringer T; Simmet NE; Scharnagl H; Bocksrucker C; Lampl C; Storch MK; Stojakovic T; Fazekas F
    PLoS One; 2013; 8(7):e68768. PubMed ID: 23894342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usefulness of midregional proadrenomedullin to predict poor outcome in patients with community acquired pneumonia.
    Gordo-Remartínez S; Calderón-Moreno M; Fernández-Herranz J; Castuera-Gil A; Gallego-Alonso-Colmenares M; Puertas-López C; Nuevo-González JA; Sánchez-Sendín D; García-Gámiz M; Sevillano-Fernández JA; Álvarez-Sala LA; Andueza-Lillo JA; de Miguel-Yanes JM
    PLoS One; 2015; 10(6):e0125212. PubMed ID: 26030588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive value of midregional pro-adrenomedullin compared to natriuretic peptides for incident cardiovascular disease and heart failure in the population-based FINRISK 1997 cohort.
    Funke-Kaiser A; Havulinna AS; Zeller T; Appelbaum S; Jousilahti P; Vartiainen E; Blankenberg S; Sydow K; Salomaa V
    Ann Med; 2014 May; 46(3):155-62. PubMed ID: 24506434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of midregional pro-adrenomedullin as a marker of organ damage and predictor of mortality in patients with sepsis.
    Bernal-Morell E; García-Villalba E; Vera MDC; Medina B; Martinez M; Callejo V; Valero S; Cinesi C; Piñera P; Alcaraz A; Marin I; Muñoz A; Cano A
    J Infect; 2018 Mar; 76(3):249-257. PubMed ID: 29246637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Midregional pro-adrenomedullin as a predictor for therapeutic response to midodrine hydrochloride in children with postural orthostatic tachycardia syndrome.
    Zhang F; Li X; Ochs T; Chen L; Liao Y; Tang C; Jin H; Du J
    J Am Coll Cardiol; 2012 Jul; 60(4):315-20. PubMed ID: 22813609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma pro-adrenomedullin but not plasma pro-endothelin predicts survival in exacerbations of COPD.
    Stolz D; Christ-Crain M; Morgenthaler NG; Miedinger D; Leuppi J; Müller C; Bingisser R; Struck J; Müller B; Tamm M
    Chest; 2008 Aug; 134(2):263-272. PubMed ID: 18490402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma mid-regional pro-adrenomedullin: A biomarker of the ischemic penumbra in hyperacute stroke.
    Ishiyama H; Tanaka T; Saito S; Koyama T; Kitamura A; Inoue M; Fukushima N; Morita Y; Koga M; Toyoda K; Kuriyama N; Urushitani M; Ihara M
    Brain Pathol; 2023 Mar; 33(2):e13110. PubMed ID: 35916272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mid-regional pro-adrenomedullin in patients with acute dyspnea: Data from the Akershus Cardiac Examination (ACE) 2 Study.
    Pervez MO; Lyngbakken MN; Myhre PL; Brynildsen J; Langsjøen EC; Høiseth AD; Christensen G; Omland T; Røsjø H
    Clin Biochem; 2017 May; 50(7-8):394-400. PubMed ID: 28065681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study.
    Khan SQ; O'Brien RJ; Struck J; Quinn P; Morgenthaler N; Squire I; Davies J; Bergmann A; Ng LL
    J Am Coll Cardiol; 2007 Apr; 49(14):1525-32. PubMed ID: 17418290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea.
    Shah RV; Truong QA; Gaggin HK; Pfannkuche J; Hartmann O; Januzzi JL
    Eur Heart J; 2012 Sep; 33(17):2197-205. PubMed ID: 22645194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of plasma midregional pro-adrenomedullin and C-terminal-pro-endothelin-1 in chronic heart failure outpatients.
    Adlbrecht C; Hülsmann M; Strunk G; Berger R; Mörtl D; Struck J; Morgenthaler NG; Bergmann A; Jakowitsch J; Maurer G; Lang IM; Pacher R
    Eur J Heart Fail; 2009 Apr; 11(4):361-6. PubMed ID: 19190023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The vasoactive peptide MR-pro-adrenomedullin in COVID-19 patients: an observational study.
    Gregoriano C; Koch D; Kutz A; Haubitz S; Conen A; Bernasconi L; Hammerer-Lercher A; Saeed K; Mueller B; Schuetz P
    Clin Chem Lab Med; 2021 Apr; 59(5):995-1004. PubMed ID: 33554516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic potential of midregional pro-adrenomedullin following decompensation for systolic heart failure: comparison with cardiac natriuretic peptides.
    Morbach C; Marx A; Kaspar M; Güder G; Brenner S; Feldmann C; Störk S; Vollert JO; Ertl G; Angermann CE;
    Eur J Heart Fail; 2017 Sep; 19(9):1166-1175. PubMed ID: 28516504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mid-regional pro-adrenomedullin in the early evaluation of acute chest pain patients.
    Haaf P; Twerenbold R; Reichlin T; Faoro J; Reiter M; Meune C; Steuer S; Bassetti S; Ziller R; Balmelli C; Campodarve I; Zellweger C; Kilchenmann A; Irfan A; Papassotiriou J; Drexler B; Mueller C
    Int J Cardiol; 2013 Sep; 168(2):1048-55. PubMed ID: 23199555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Midregional proadrenomedullin and its change predicts recurrent major coronary events and heart failure in stable coronary heart disease patients: the LIPID study.
    Funke-Kaiser A; Mann K; Colquhoun D; Zeller T; Hunt D; Simes J; Sullivan D; Sydow K; West M; White H; Blankenberg S; Tonkin AM;
    Int J Cardiol; 2014 Mar; 172(2):411-8. PubMed ID: 24508492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Midregional proadrenomedullin for prediction of cardiovascular events in coronary artery disease: results from the AtheroGene study.
    Wild PS; Schnabel RB; Lubos E; Zeller T; Sinning CR; Keller T; Tzikas S; Lackner KJ; Peetz D; Rupprecht HJ; Bickel C; Morgenthaler NG; Papassotiriou J; Tiret L; Münzel T; Blankenberg S
    Clin Chem; 2012 Jan; 58(1):226-36. PubMed ID: 22065157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thirty and ninety days mortality predictive value of admission and in-hospital procalcitonin and mid-regional pro-adrenomedullin testing in patients with dyspnea. Results from the VERyfing DYspnea trial.
    Travaglino F; Russo V; De Berardinis B; Numeroso F; Catania P; Cervellin G; Nigra SG; Geraci F; Bressan MA; Guerrini S; Cavazza M; Folli C; Monzani V; Battista S; Mengozzi G; Noto P; Carpinteri G; Semplicini A; Stella F; Ingrassia S; Moscatelli P; Giuntini P; Salerno G; Cardelli P; Di Somma S
    Am J Emerg Med; 2014 Apr; 32(4):334-41. PubMed ID: 24559907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pro-Adrenomedullin predicts 10-year all-cause mortality in community-dwelling patients: a prospective cohort study.
    Odermatt J; Meili M; Hersberger L; Bolliger R; Christ-Crain M; Briel M; Bucher HC; Mueller B; Schuetz P
    BMC Cardiovasc Disord; 2017 Jul; 17(1):178. PubMed ID: 28676115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mid-regional pro-adrenomedullin and copeptin to predict short-term prognosis of COPD exacerbations: a multicenter prospective blinded study.
    Dres M; Hausfater P; Foissac F; Bernard M; Joly LM; Sebbane M; Philippon AL; Gil-Jardiné C; Schmidt J; Maignan M; Treluyer JM; Roche N
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1047-1056. PubMed ID: 28408815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic and prognostic role of procalcitonin (PCT) and MR-pro-Adrenomedullin (MR-proADM) in bacterial infections.
    Angeletti S; Spoto S; Fogolari M; Cortigiani M; Fioravanti M; De Florio L; Curcio B; Cavalieri D; Costantino S; Dicuonzo G
    APMIS; 2015 Sep; 123(9):740-8. PubMed ID: 26058482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.